Nanoparticles deliver one-two therapeutic punch to kill tumor cells

Dec 17, 2010

The standard approach to cancer therapy today is to mix and match chemotherapy drugs in order to attack tumors in multiple ways. Now, two separate teams of investigators have demonstrated that using nanoparticles to deliver multiple drugs simultaneously can produce a synergistic effect that boosts the cell-killing ability of both drugs.

In one study, a team of investigators at Northwestern University has shown that they can combine two powerful but extremely toxic anticancer agents - and - in one polymer nanoparticle, producing a substantial boost in their ability of the combination to destroy tumors. In addition, the two-in-one nanoparticle reduces the amount of both drugs needed to kill cancer cells, which presumably would reduce the associated with these drugs.

SonBinh Nguyen and Thomas O'Halloran led this study, which was published in the . Dr. O'Halloran is the co-principal investigator of one of 12 Cancer Platform Partnerships funded by the National Cancer Institute Alliance for Nanotechnology in Cancer. He is also a member of the Northwestern University Center for Cancer Nanotechnology Excellence (CCNE), which is also part of the Alliance for Nanotechnology in Cancer.

Though originally designed to carry arsenic trioxide to solid tumors, the used in this study are proving to be quite versatile in their ability to ferry a wide range of cargos to malignancies. In this study, the investigators wanted to see if delivering two drugs in one nanoparticle offered any advantages of delivering them without the nanoparticle or in separate nanoparticles. The nanoparticles, which the researchers call nanobins, are made by encasing a liposome inside a pH-responsive polymer cage. In this case, doxorubicin is entrapped within the liposome's core, while cisplatin was entrapped in the polymer cage.

In an initial set of experiments, the investigators determined that a 5 to 1 ratio of cisplatin to doxorubicin was the most effective at treating ovarian tumors when the two drugs were combined in the same nanoparticle. When the two drugs were administered at this ratio but with each in its own nanoparticle, the combination was not only less effective at killing malignant cells, but the two drugs appeared to be interfering with each other, a phenomenon often observed in clinical practice. Administering the two drugs in the same nanoparticle ensures that the drugs are hitting their intracellular targets at the same time, which is what likely leads to the synergism observed in this study.

Meanwhile, Mansoor Amiji and Zhenfeng Duan, co-principle investigators of the Nanotechnology Platform Partnership at Northeastern University, have shown that a different type of polymer nanoparticle can also deliver two anticancer agents simultaneously and as a result can kill that have become resistant to drug therapy. In this case, the researchers synthesized biocompatible polymer nanoparticles that entrapped paclitaxel and lonidamine and that targeted the epidermal growth factor receptor (EGFR) that is overexpressed on highly aggressive tumors. When added to growing in culture, the nanoparticle containing both drugs was far more effective at killing the drug-resistance cells than when the two drugs were co-administered in separate nanoparticles. The investigators reported their findings in the journal Molecular Pharmaceutics.

In a separate set of experiments, the results of which were published in the journal Angewandte Chemie International Edition, Drs. Nguyen and O'Halloran, joined by Thomas Meade, another member of the Northwestern CCNE, demonstrated that nanobins can also co-deliver a therapeutic and magnetic resonance imaging agent to tumors. In this study, the researchers loaded the anticancer agent gemcitabine into the nanobin's core and added a gadolinium magnetic resonance contrast agent to the nanobin's surface. When added to mouse tumor cells, the nanobins were taken up rapidly and the nanobins were clearly visible in magnetic resonance images. In addition, the nanoparticles released their gemcitabine payload once the nanobins were taken up by the cultured cells.

Explore further: Scientists convert microbubbles to nanoparticles

More information: This work, which is detailed in three papers, was supported in part by the NCI Alliance for Nanotechnology in Cancer. Abstracts of the papers are available at the journals' websites.
Journal of the American Chemical Society paper
Molecular Pharmaceutics paper
Angewandte Chemie International Edition paper

Related Stories

Nanoparticles Overcome Anticancer Drug Resistance

Jun 12, 2006

Too often, chemotherapy fails to cure cancer because some tumor cells develop resistance to multiple anticancer drugs. In most cases, resistance develops when cancer cells begin expressing a protein, known as p-glycoprotein, ...

Double-Duty Nanoparticles Overcome Drug Resistance in Tumors

Jun 14, 2007

Cancer cells, like bacteria, can develop resistance to drug therapy. In fact, research suggests strongly that multidrug resistant cancer cells that remain alive after chemotherapy are responsible for the reappearance of tumors ...

New arsenic nanoparticle blocks aggressive breast cancer

Jul 15, 2010

You can teach an old drug new chemotherapy tricks. Northwestern University researchers took a drug therapy proven for blood cancers but ineffective against solid tumors, packaged it with nanotechnology and got it to combat ...

Two-In-One Punch Knocks Out Drug Resistant Cancer Cells

Nov 04, 2009

( -- Cancer cells, like bacteria, can develop resistance to drug therapy, leading to relapse of disease. One approach showing promise in overcoming multidrug resistance in tumors is to combine two different anticancer ...

Recommended for you

Nanoparticles release drugs to reduce tooth decay

6 hours ago

Therapeutic agents intended to reduce dental plaque and prevent tooth decay are often removed by saliva and the act of swallowing before they can take effect. But a team of researchers has developed a way ...

Combining magnetism and light to fight cancer

10 hours ago

By combining, in a liposome, magnetic nanoparticles and photosensitizers that are simultaneously and remotely activated by external physical stimuli (a magnetic field and light), scientists at the Laboratoire ...

Scientists convert microbubbles to nanoparticles

Mar 30, 2015

Biomedical researchers led by Dr. Gang Zheng at Princess Margaret Cancer Centre have successfully converted microbubble technology already used in diagnostic imaging into nanoparticles that stay trapped in tumours to potentially ...

Designer's toolkit for dynamic DNA nanomachines

Mar 26, 2015

The latest DNA nanodevices created at the Technische Universitaet Muenchen (TUM)—including a robot with movable arms, a book that opens and closes, a switchable gear, and an actuator—may be intriguing ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Dec 23, 2010
Just imagine a molecular motor and a sensor guiding this to cancer cells, so that the drugs are administered to all cancer cells, and ONLY cancer cells.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.